BMC nephrology
Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study.
Juan Pei, Xiuhua Xu, Ruihong Huang, Xuejuan Sun, Jun Zhang, Xing Chen, Lijing Yao, Hengyuan Zhang, Leping Shao, Yinan Li
Published: 202510.1186/s12882-025-04708-w
Abstract
OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of low- to medium-dose (160 mg/W or 80 mg/W) telitacicept in adults at high risk of progression IgA nephropathy. METHODS: This was a single-center retrospective study. The s…
Preview only. Read the full abstract at the source